These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: 3-Deacetoxy-7-(alpha-amino-1-cyclohexenylacetamido) cephalosporanic acid (SCE-100), a new semisynthetic cephalosporin. I. Comparative in vitro antibacterial activities of SCE-100 and cephalexin (CEX).
    Author: Yamazaki T, Tsuchiya K.
    Journal: J Antibiot (Tokyo); 1976 May; 29(5):559-65. PubMed ID: 956045.
    Abstract:
    3-Deacetoxy-7(alpha-amino)-1-cyclohexenylacetamido) cephalosporanic acid (SCE-100) has a potent antibacterial activity against Gram-positive and Gram-negative bacteria. The minimum inhibitory concentration of SCE-100 is 0.2 approximately 12.5 mug/ml against Gram-positive bacteria including penicillin G-resistant Staphylococcus aureus and 6.25 approximately 100 mug/ml against Gram-negative bacteria. SCE-100 inhibits clinically isolated strains of penicillin G-resistant S. aureus and ampicillin-resistant Escherichia coli, as well as the corresponding sensitive strains. The activity of SCE-100 is enhanced by decreasing the inoculum size and is only slightly influenced by medium pH, difference of medium composition and the addition of horse serum. SCE-100 has bactericidal activity against S. aureus and E. coli. There is a stepwise development of in vitro bacterial resistance to SCE-100 by serial transfer of organisms into a liquid medium containing SCE-100. Cross resistance was observed between SCE-100 and other tested cephalosporins.
    [Abstract] [Full Text] [Related] [New Search]